A novel vaccine formulation candidate based on lipooligosaccharides and pertussis toxin against Bordetella pertussis
Pertussis is a severe human respiratory tract infectious disease caused by Bordetella pertussis that primarily affects infants and young children. However, the acellular pertussis vaccine currently administered can induce antibody and Th2 immune responses but fails to prevent the nasal colonization...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-04-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1124695/full |
_version_ | 1797838673957355520 |
---|---|
author | Jingjing Gao Linlin Huang Shuquan Luo Ruijie Qiao Fanglei Liu Xin Li Xin Li |
author_facet | Jingjing Gao Linlin Huang Shuquan Luo Ruijie Qiao Fanglei Liu Xin Li Xin Li |
author_sort | Jingjing Gao |
collection | DOAJ |
description | Pertussis is a severe human respiratory tract infectious disease caused by Bordetella pertussis that primarily affects infants and young children. However, the acellular pertussis vaccine currently administered can induce antibody and Th2 immune responses but fails to prevent the nasal colonization and transmission of B. pertussis, causing a resurgence of pertussis, so improved pertussis vaccines are urgently needed. In this study, we created a two-component pertussis vaccine candidate containing a conjugate prepared from oligosaccharides and pertussis toxin. After demonstrating the ability of the vaccine to induce a mixed Th1/Th2/Th17 profile in a mouse model, the strong in vitro bactericidal activity and IgG response of the vaccine were further demonstrated. In addition, the vaccine candidate further induced efficient prophylactic effects against B. pertussis in a mouse aerosol infection model. In summary, the vaccine candidate in this paper induces antibodies with bactericidal activity to provide high protection, shorten the duration of bacterial existence, and further reduce disease outbreaks. Therefore, the vaccine has the potential to be the next generation of pertussis vaccines. |
first_indexed | 2024-04-09T15:44:39Z |
format | Article |
id | doaj.art-da8d23b99b8542aeac285045f9baa956 |
institution | Directory Open Access Journal |
issn | 1664-3224 |
language | English |
last_indexed | 2024-04-09T15:44:39Z |
publishDate | 2023-04-01 |
publisher | Frontiers Media S.A. |
record_format | Article |
series | Frontiers in Immunology |
spelling | doaj.art-da8d23b99b8542aeac285045f9baa9562023-04-27T04:51:20ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-04-011410.3389/fimmu.2023.11246951124695A novel vaccine formulation candidate based on lipooligosaccharides and pertussis toxin against Bordetella pertussisJingjing Gao0Linlin Huang1Shuquan Luo2Ruijie Qiao3Fanglei Liu4Xin Li5Xin Li6The First R&D Laboratory, Lanzhou Institute of Biological Products Company Limited, Lanzhou, ChinaDepartment of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Engineering and Technology Research Center for Pediatric Drug Development, Shandong Medicine and Health Key Laboratory of Clinical Pharmacy, Jinan, ChinaThe First R&D Laboratory, Lanzhou Institute of Biological Products Company Limited, Lanzhou, ChinaThe First R&D Laboratory, Lanzhou Institute of Biological Products Company Limited, Lanzhou, ChinaThe First R&D Laboratory, Lanzhou Institute of Biological Products Company Limited, Lanzhou, ChinaThe First R&D Laboratory, Lanzhou Institute of Biological Products Company Limited, Lanzhou, ChinaState Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, ChinaPertussis is a severe human respiratory tract infectious disease caused by Bordetella pertussis that primarily affects infants and young children. However, the acellular pertussis vaccine currently administered can induce antibody and Th2 immune responses but fails to prevent the nasal colonization and transmission of B. pertussis, causing a resurgence of pertussis, so improved pertussis vaccines are urgently needed. In this study, we created a two-component pertussis vaccine candidate containing a conjugate prepared from oligosaccharides and pertussis toxin. After demonstrating the ability of the vaccine to induce a mixed Th1/Th2/Th17 profile in a mouse model, the strong in vitro bactericidal activity and IgG response of the vaccine were further demonstrated. In addition, the vaccine candidate further induced efficient prophylactic effects against B. pertussis in a mouse aerosol infection model. In summary, the vaccine candidate in this paper induces antibodies with bactericidal activity to provide high protection, shorten the duration of bacterial existence, and further reduce disease outbreaks. Therefore, the vaccine has the potential to be the next generation of pertussis vaccines.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1124695/fullBordetella pertussislipooligosaccharidesconjugate vaccinepertussis toxinProtection |
spellingShingle | Jingjing Gao Linlin Huang Shuquan Luo Ruijie Qiao Fanglei Liu Xin Li Xin Li A novel vaccine formulation candidate based on lipooligosaccharides and pertussis toxin against Bordetella pertussis Frontiers in Immunology Bordetella pertussis lipooligosaccharides conjugate vaccine pertussis toxin Protection |
title | A novel vaccine formulation candidate based on lipooligosaccharides and pertussis toxin against Bordetella pertussis |
title_full | A novel vaccine formulation candidate based on lipooligosaccharides and pertussis toxin against Bordetella pertussis |
title_fullStr | A novel vaccine formulation candidate based on lipooligosaccharides and pertussis toxin against Bordetella pertussis |
title_full_unstemmed | A novel vaccine formulation candidate based on lipooligosaccharides and pertussis toxin against Bordetella pertussis |
title_short | A novel vaccine formulation candidate based on lipooligosaccharides and pertussis toxin against Bordetella pertussis |
title_sort | novel vaccine formulation candidate based on lipooligosaccharides and pertussis toxin against bordetella pertussis |
topic | Bordetella pertussis lipooligosaccharides conjugate vaccine pertussis toxin Protection |
url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1124695/full |
work_keys_str_mv | AT jingjinggao anovelvaccineformulationcandidatebasedonlipooligosaccharidesandpertussistoxinagainstbordetellapertussis AT linlinhuang anovelvaccineformulationcandidatebasedonlipooligosaccharidesandpertussistoxinagainstbordetellapertussis AT shuquanluo anovelvaccineformulationcandidatebasedonlipooligosaccharidesandpertussistoxinagainstbordetellapertussis AT ruijieqiao anovelvaccineformulationcandidatebasedonlipooligosaccharidesandpertussistoxinagainstbordetellapertussis AT fangleiliu anovelvaccineformulationcandidatebasedonlipooligosaccharidesandpertussistoxinagainstbordetellapertussis AT xinli anovelvaccineformulationcandidatebasedonlipooligosaccharidesandpertussistoxinagainstbordetellapertussis AT xinli anovelvaccineformulationcandidatebasedonlipooligosaccharidesandpertussistoxinagainstbordetellapertussis AT jingjinggao novelvaccineformulationcandidatebasedonlipooligosaccharidesandpertussistoxinagainstbordetellapertussis AT linlinhuang novelvaccineformulationcandidatebasedonlipooligosaccharidesandpertussistoxinagainstbordetellapertussis AT shuquanluo novelvaccineformulationcandidatebasedonlipooligosaccharidesandpertussistoxinagainstbordetellapertussis AT ruijieqiao novelvaccineformulationcandidatebasedonlipooligosaccharidesandpertussistoxinagainstbordetellapertussis AT fangleiliu novelvaccineformulationcandidatebasedonlipooligosaccharidesandpertussistoxinagainstbordetellapertussis AT xinli novelvaccineformulationcandidatebasedonlipooligosaccharidesandpertussistoxinagainstbordetellapertussis AT xinli novelvaccineformulationcandidatebasedonlipooligosaccharidesandpertussistoxinagainstbordetellapertussis |